



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: 04/13/2018

TO: File for BLA 125276/S-115

THROUGH: Nikolay Nikolov, MD

FROM: Rachel Glaser, MD

SUBJECT: **Clinical Primary Review**

APPLICATION/DRUG: **BLA 125276/S-115 ACTEMRA (tocilizumab)**

Genentech submitted supplement 115 to BLA 125276 on November 13, 2017 seeking to revise the prescribing information (PI) with updated pediatric information regarding treatment with intravenous tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis in patients less than 2 years of age and a determination that the postmarketing requirement and the relevant portion of the pediatric written request have been fulfilled. No indications are being sought in the current supplement. The submitted data includes the results of Study NP25737, an open-label PK and safety study in patients < 2 years of age with SJIA who were treated with intravenous TCZ 12 mg/kg every 2 weeks for 12 weeks.

I recommend approval of supplement 115 with updates to Section 8.4 of the PI pending the finalized review by the clinical pharmacology review team and provided agreement can be reached with the Applicant on revisions to the proposed label.

The clinical review has been completed. A multi-disciplinary unireview has been used for this supplement, and the clinical review will be archived as part of this unireview.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RACHEL GLASER
04/12/2018

NIKOLAY P NIKOLOV
04/12/2018